Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
several companies
|
| gptkbp:advertising |
expansion into new markets
|
| gptkbp:awards |
various industry awards
|
| gptkbp:brand |
strong_brand_recognition_in_Europe
|
| gptkbp:budget |
published annually
|
| gptkbp:businessModel |
B2B_and_B2C_operations
|
| gptkbp:CEO |
Mr._Smith
|
| gptkbp:clinicalTrials |
ongoing
conducts clinical research studies advanced clinical development programs |
| gptkbp:collaborations |
academic institutions
collaborations with research institutions. partnerships with hospitals for clinical trials |
| gptkbp:community_involvement |
healthcare_initiatives
|
| gptkbp:competitors |
conducts market analysis regularly
|
| gptkbp:customerBase |
diverse customer base
|
| gptkbp:employees |
over 1,000
|
| gptkbp:financial_aid |
financially stable company
|
| gptkbp:financialPerformance |
growing revenue
|
| gptkbp:founded |
1901
|
| gptkbp:founder |
gptkb:Ernst_Richter
|
| gptkbp:global_presence |
international markets
|
| gptkbp:headquarters |
gptkb:Wien,_Austria
|
| https://www.w3.org/2000/01/rdf-schema#label |
Richter Pharma AG
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:innovation |
focus on innovation in drug development
|
| gptkbp:investmentFocus |
publicly traded company
investments in technology R&D investments |
| gptkbp:market |
Europe
significant_market_share_in_Europe |
| gptkbp:operates_in |
over 30 countries
|
| gptkbp:partnerships |
various international pharmaceutical companies
collaborations with biotech firms |
| gptkbp:patentCitation |
numerous patents in pharmaceuticals
|
| gptkbp:productLine |
generic drugs
branded drugs diverse product pipeline |
| gptkbp:products |
prescription drugs
global distribution network |
| gptkbp:regulatoryCompliance |
EMA_approvals
FDA_approvals |
| gptkbp:research |
gptkb:Dr._John_Doe
|
| gptkbp:research_areas |
cardiology
oncology infectious diseases gynecology urology |
| gptkbp:research_focus |
biotechnology
|
| gptkbp:revenue |
over €500 million
|
| gptkbp:social_responsibility |
active CSR initiatives
|
| gptkbp:specializesIn |
central nervous system drugs
|
| gptkbp:stockExchange |
RCH
|
| gptkbp:subsidiary |
gptkb:Richter-Helm_BioLogics_GmbH
|
| gptkbp:supplyChain |
efficient supply chain management
|
| gptkbp:sustainability_initiatives |
environmental responsibility programs
|
| gptkbp:training |
ongoing employee training programs
|
| gptkbp:website |
www.richter-pharma.com
|